Novel pharmacotherapy targeting the positive symptoms of schizophrenia

References

• Buoli M, Dell’osso B, Zaytseva Y, et al. Duration of untreated illness (DUI) and schizophrenia sub-types: a collaborative study between the universities of Milan and Moscow. Int J Soc Psychiatry. 2013;59(8):765–770. doi: 10.1177/0020764012456807
   PubMed Web of Science ®Google Scholar
• Vita A, Barlati S, De Peri L, et al. Schizophrenia. Lancet. 2016;388(10051):1280. doi: 10.1016/S0140-6736(16)31674-9
   PubMed Web of Science ®Google Scholar
• Buoli M, Caldiroli A, Panza G, et al. Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig. 2012;9(4):354. doi: 10.4306/pi.2012.9.4.354
   PubMed Web of Science ®Google Scholar
• Galderisi S, Mucci A, Bitter I, et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European first episode schizophrenia trial. Eur Neuropsychopharmacol. 2013;23(3):196–204. doi: 10.1016/j.euroneuro.2012.04.019
   PubMed Web of Science ®Google Scholar
• Ekinci O, Ekinci A. Association between insight, cognitive insight, positive symptoms and violence in patients with schizophrenia. Nord J Psychiatry. 2013;67(2):116–123. doi: 10.3109/08039488.2012.687767
   PubMed Web of Science ®Google Scholar
• Salim Z, Haddad C, Obeid S, et al. CommAnd Voices And Aggression In A Lebanese Sample Patients With Schizophrenia. Psychiatry Danub. 2021;33(1):27–34. doi: 10.24869/psyd.2021.27
   PubMed Web of Science ®Google Scholar
• Comparelli A, Corigliano V, Lamis DA, et al. Positive symptoms and social cognition impairment affect severity of suicidal ideation in schizophrenia. Schizophr Res. 2018;193:470–471. doi:10.1016/j.schres.2017.07.027
   PubMed Web of Science ®Google Scholar
• Buchy L, Torres IJ, Liddle PF, et al. Symptomatic determinants of insight in schizophrenia spectrum disorders. Compr Psychiatry. 2009;50(6):578–583. doi: 10.1016/j.comppsych.2009.01.007
   PubMed Web of Science ®Google Scholar
• Zhou Y, Rosenheck R, Mohamed S, et al. Insight in inpatients with schizophrenia: relationship to symptoms and neuropsychological functioning. Schizophr Res. 2015;161(2–3):376–381. doi: 10.1016/j.schres.2014.12.009
   PubMed Web of Science ®Google Scholar
• Bora E, Gökçen S, Kayahan B, et al. Deficits of social-cognitive and social-perceptual aspects of theory of mind in remitted patients with schizophrenia: effect of residual symptoms. J Nerv Ment Dis. 2008;196(2):95–99. doi: 10.1097/NMD.0b013e318162a9e1
   PubMed Web of Science ®Google Scholar
• Tsai S, Sajatovic M, Hsu J, et al. Body mass index, residual psychotic symptoms, and inflammation associated with brain volume reduction in older patients with schizophrenia. Int J Geriatr Psychiatry. 2020;35(7):728–736. doi: 10.1002/gps.5291
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry. 1987;48 Suppl:13–19.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 2020 Feb 21;16: 519–534. doi: 10.2147/NDT.S225643.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Rico-Villademoros F, García-Rizo C, et al. Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies. Adv Ther. 2021;38(5):2491–2512. doi: 10.1007/s12325-021-01689-8
   PubMed Web of Science ®Google Scholar
• Ventriglio A, Bellomo A, Ricci F, et al. New pharmacological targets for the treatment of schizophrenia: a literature review. CTMC. 2021;21(16):1500–1516. doi: 10.2174/1568026621666210701103147
   Google Scholar
• Nucifora FC, Woznica E, Lee BJ, et al. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257. doi:10.1016/j.nbd.2018.08.016
   PubMed Web of Science ®Google Scholar
• Capuzzi E, Ceresa A, Caldiroli A, et al. The relation between the plasma concentrations of long-acting atypical antipsychotics and clinical effectiveness in patients affected by schizophrenia or schizoaffective disorder: a comprehensive overview. CPD. 2021;27(39):4070–4077. doi: 10.2174/1381612827666210830095349
   Google Scholar
• Auxilia AM, Buoli M, Caldiroli A, et al. High rate of discontinuation during long-acting injectable antipsychotic treatment in patients with psychotic disorders. Biomedicines. 2023;11(2):314. doi: 10.3390/biomedicines11020314
   PubMed Web of Science ®Google Scholar
• Lähteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273–1284. doi: 10.1007/s40265-021-01556-4
   PubMed Web of Science ®Google Scholar
• Biagi E, Capuzzi E, Colmegna F, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017;34(5):1036–1048. doi: 10.1007/s12325-017-0507-x
   PubMed Web of Science ®Google Scholar
• Armijo-Olivo S, Stiles CR, Hagen NA, et al. Assessment of study quality for systematic reviews: a comparison of the Cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool: methodological research: quality assessment for systematic reviews. J Eval Clin Pract. 2012;18(1):12–18. doi: 10.1111/j.1365-2753.2010.01516.x
   PubMed Web of Science ®Google Scholar
• Silver H, Barash I, Aharon N, et al. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol. 2000;15(5):257–261. doi: 10.1097/00004850-200015050-00002
   PubMed Web of Science ®Google Scholar
• Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol. 1998;18(3):208–211. doi: 10.1097/00004714-199806000-00005
   PubMed Web of Science ®Google Scholar
• Haji Seyed Javadi A, Shafikhani AA, Zamir SM, et al. Evaluation of the effect of fluvoxamine in patients with schizophrenia under risperidone treatment: a clinical trial. J Clin Psychopharmacol. 2018;38(2):119–124. doi: 10.1097/JCP.0000000000000850
   PubMed Web of Science ®Google Scholar
• Shi H, Xu J, Lang X, et al. Comparison of efficacy and safety between low-dose ziprasidone in combination with sertraline and ziprasidone monotherapy for treatment-resistant patients with acute exacerbation schizophrenia: a randomized controlled trial. Front Pharmacol. 2022;13:863588. doi:10.3389/fphar.2022.863588
   PubMed Web of Science ®Google Scholar
• Nikbakhat M-R, Arabzadeh S, Zeinoddini A, et al. Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Pharmacopsychiatry. 2016;49(4):162–169. doi: 10.1055/s-0042-101557
   PubMed Web of Science ®Google Scholar
• Decina P, Mukherjee S, Bocola V, et al. Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. PS. 1994;45(12):1220–1223. doi: 10.1176/ps.45.12.1220
   Google Scholar
• Hayashi T, Yokota N, Takahashi T, et al. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1997;12(4):199–206. doi: 10.1097/00004850-199707000-00003
   PubMed Web of Science ®Google Scholar
• Moazen-Zadeh E, Bayanati S, Ziafat K, et al. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2020;34(5):506–513. doi: 10.1177/0269881120909416
   PubMed Web of Science ®Google Scholar
• Shoja Shafti S, Jafarabad MS, Azizi R. Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor. Ther Adv Psychopharmacol. 2015;5(5):263–270. doi: 10.1177/2045125315591953
   PubMed Web of Science ®Google Scholar
• Berk M, Gama CS, Sundram S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol Clin Exp. 2009;24(3):233–238. doi: 10.1002/hup.1017
   PubMed Web of Science ®Google Scholar
• Joffe G, Terevnikov V, Joffe M, et al. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2009;108(1–3):245–251. doi: 10.1016/j.schres.2008.12.002
   PubMed Web of Science ®Google Scholar
• Terevnikov V, Stenberg J-H, Joffe M, et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Hum Psychopharmacol Clin Exp. 2010;25(6):431–438. doi: 10.1002/hup.1137
   PubMed Web of Science ®Google Scholar
• Shiloh R, Zemishlany Z, Aizenberg D, et al. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int Clin Psychopharmacol. 2002;17(2):59–64. doi: 10.1097/00004850-200203000-00003
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Hallikainen T, Ryynänen O-P, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry. 2003;54(11):1241–1248. doi: 10.1016/S0006-3223(03)00524-9
   PubMed Web of Science ®Google Scholar
• Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biological Psychiatry. 2004;56(6):441–446. doi: 10.1016/j.biopsych.2004.06.029
   PubMed Web of Science ®Google Scholar
• Javahery T, Tayyebi A, Belyad M. The effect of adding pregabalin to conventional treatment in schizophrenia patients, for improving positive, negative and general symptoms of these patient. Int J Med Res Health Sci. 2016;5:282–287.
   Google Scholar
• Ibrahim I, Tobar S, Fathi W, et al. Randomized controlled trial of adjunctive valproate for cognitive remediation in early course schizophrenia. J Psychiatr Res. 2019;118:66–72. doi:10.1016/j.jpsychires.2019.08.011
   PubMed Web of Science ®Google Scholar
• Ohlmeier MD, Jahn K, Wilhelm-Gössling C, et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology. 2007;55(2):81–88. doi: 10.1159/000103906
   PubMed Web of Science ®Google Scholar
• Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. AJP. 1999;156(1):145–147. doi: 10.1176/ajp.156.1.145
   Google Scholar
• Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry. 2004;55(2):165–171. doi: 10.1016/S0006-3223(03)00707-8
   PubMed Web of Science ®Google Scholar
• Van Berckel B. D-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21(2):203–210. doi: 10.1016/S0893-133X(99)00014-7
   PubMed Web of Science ®Google Scholar
• Tsai G, Yang P, Chung L-C, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry. 1998;44(11):1081–1089. doi: 10.1016/S0006-3223(98)00279-0
   PubMed Web of Science ®Google Scholar
• Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, et al. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther. 1999;24(5):369–374. doi: 10.1046/j.1365-2710.1999.00238.x
   PubMed Web of Science ®Google Scholar
• Rezaei F, Mohammad-Karimi M, Seddighi S, et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2013;33(3):336–342. doi: 10.1097/JCP.0b013e31828b50a7
   PubMed Web of Science ®Google Scholar
• Veerman SRT, Schulte PFJ, Smith JD, et al. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med. 2016;46(9):1909–1921. doi: 10.1017/S0033291716000398
   PubMed Web of Science ®Google Scholar
• De Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009;70(10):1416–1423. doi: 10.4088/JCP.08m04935gry
   PubMed Web of Science ®Google Scholar
• Omranifard V, Rajabi F, Mohammadian-Sichani M, et al. The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. Actas Esp Psiquiatr. 2017;45(3):108–115.
   PubMed Web of Science ®Google Scholar
• Csernansky JG. Double-blind comparison of Alprazolam, Diazepam, and Placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry. 1988;45(7):655. doi: 10.1001/archpsyc.1988.01800310063008
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM. Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients: preliminary Results. Arch Gen Psychiatry. 1988;45(7):664. doi: 10.1001/archpsyc.1988.01800310072009
   PubMed Web of Science ®Google Scholar
• Javitt DC. Bitopertin in schizophrenia: glass half full? Lancet Psychiatry. 2016;3(12):1092–1093. doi: 10.1016/S2215-0366(16)30354-6
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirola D, Wang A, Abi-Saab D, et al. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – results from the CandleLyte study. Eur Neuropsychopharmacol. 2014;24(7):1024–1036. doi: 10.1016/j.euroneuro.2014.03.007
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirola D, Iwata N, Sameljak S, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry. 2016;3(12):1115–1128. doi: 10.1016/S2215-0366(16)30344-3
   PubMed Web of Science ®Google Scholar
• Buoli M, Altamura A. May non-antipsychotic drugs improve cognition of schizophrenia patients? Pharmacopsychiatry. 2015;48(2):41–50. doi: 10.1055/s-0034-1396801
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Malhotra AK, Meltzer HY, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacol. 2008;33(6):1217–1228. doi: 10.1038/sj.npp.1301499
   PubMed Web of Science ®Google Scholar
• Middleton HC, Sharma A, Agouzoul D, et al. Idazoxan potentiates rather than antagonizes some of the cognitive effects of clonidine. Psychopharmacology. 1999;145(4):401–411. doi: 10.1007/s002130051074
   PubMed Web of Science ®Google Scholar
• Litman RE, Su T-P, Potter WZ, et al. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br J Psychiatry. 1996;168(5):571–579. doi: 10.1192/bjp.168.5.571
   PubMed Web of Science ®Google Scholar
• Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurotherapeutics. 2016;16(2):131–144. doi: 10.1586/14737175.2016.1135735
   PubMed Web of Science ®Google Scholar
• Lasser RA, Dirks B, Nasrallah H, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacol. 2013;38(11):2140–2149. doi: 10.1038/npp.2013.111
   PubMed Web of Science ®Google Scholar
• Carpenter MD, Winsberg BG, Camus LA. Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol. 1992;12(4):273–275. doi: 10.1097/00004714-199208000-00010
   PubMed Web of Science ®Google Scholar
• Sharma RP, Javaid JI, Pandey GN, et al. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biological Psychiatry. 1991;30(5):459–466. doi: 10.1016/0006-3223(91)90307-8
   PubMed Web of Science ®Google Scholar
• Repantis D, Bovy L, Ohla K, et al. Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine. Psychopharmacology. 2021;238(2):441–451. doi: 10.1007/s00213-020-05691-w
   PubMed Web of Science ®Google Scholar
• Shoja Shafti S, Akbari S. Intractability of deficit syndrome of schizophrenia against adjunctive modafinil. J Clin Psychopharmacol. 2016;36(1):45–49. doi: 10.1097/JCP.0000000000000437
   PubMed Web of Science ®Google Scholar
• Gerlach M, Youdim MBH, Riederer P. Pharmacology of selegiline. Neurology. 1996;47(Issue 6, Supplement 3):137S–145S. doi: 10.1212/WNL.47.6_Suppl_3.137S
   Web of Science ®Google Scholar
• Bodkin JA, Siris SG, Bermanzohn PC, et al. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with Schizophrenia. AJP. 2005;162(2):388–390. doi: 10.1176/appi.ajp.162.2.388
   Google Scholar
• Çakici N, van Beveren NJM, Judge-Hundal G, et al. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49(14):2307–2319. doi: 10.1017/S0033291719001995
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90(1–3):179–185. doi: 10.1016/j.schres.2006.11.016
   PubMed Web of Science ®Google Scholar
• Malaguarnera M. Influence of resveratrol on the immune response. Nutrients. 2019;11(5):946. doi:10.3390/nu11050946.
   PubMed Web of Science ®Google Scholar
• Samaei A, Moradi K, Bagheri S, et al. Resveratrol adjunct therapy for negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Int J Neuropsychopharmacol. 2020;23(12):775–782. doi: 10.1093/ijnp/pyaa006
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Weiner E, Kelly DL, et al. Anti-inflammatory combination therapy for the treatment of schizophrenia. J Clin Psychopharmacol. 2020;40(5):444–450. doi: 10.1097/JCP.0000000000001253
   PubMed Web of Science ®Google Scholar
• Shay KP, Moreau RF, Smith EJ, et al. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta Gen Subj. 2009;1790(10):1149–1160. doi: 10.1016/j.bbagen.2009.07.026
   PubMed Web of Science ®Google Scholar
• Mishra A, Reeta KH, Sarangi SC, et al. Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial. Psychopharmacology. 2022;239(11):3525–3535. doi: 10.1007/s00213-022-06225-2
   PubMed Web of Science ®Google Scholar
• De Lima DN, Costa Filho CWL, Frota IJ, et al. α-Lipoic acid as adjunctive treatment for schizophrenia: a randomized double-blind study. J Clin Psychopharmacol. 2023;43(1):39–45. doi: 10.1097/JCP.0000000000001639
   PubMed Web of Science ®Google Scholar
• Deepmala D., Slattery J., Kumar, N., et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neuroscience & Biobehavioral Reviews. 2015;55:294–321. doi:10.1016/j.neubiorev.2015.04.015
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biological Psychiatry. 2008;64(5):361–368. doi: 10.1016/j.biopsych.2008.03.004
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Berk M, Venugopal K, et al. Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry. 2015;57:69–75. doi:10.1016/j.pnpbp.2014.10.002
   PubMed Web of Science ®Google Scholar
• Breier A, Liffick E, Hummer TA, et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018;199:395–402. doi:10.1016/j.schres.2018.03.012
   PubMed Web of Science ®Google Scholar
• Clayton P, Hill M, Bogoda N, et al. Palmitoylethanolamide: a natural compound for health management. IJMS. 2021;22(10):5305. doi: 10.3390/ijms22105305
   Google Scholar
• Salehi A, Namaei P, TaghaviZanjani F, et al. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: a randomized, double-blinded, placebo-controlled trial. Psychiatry Res. 2022;316:114737. doi:10.1016/j.psychres.2022.114737
   PubMed Web of Science ®Google Scholar
• Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an old drug with new tricks. IJMS. 2019;20(20):5023. doi: 10.3390/ijms20205023
   Google Scholar
• Chaudhry IB, Husain MO, Khoso AB, et al. A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis. Transl Psychiatry. 2020;10(1):415. doi: 10.1038/s41398-020-01095-8
   PubMed Web of Science ®Google Scholar
• Bassett B, Subramaniyam S, Fan Y, et al. Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via blocking microglia activation/phagocytosis. Brain Behav Immun. 2021;91:519–530. doi:10.1016/j.bbi.2020.11.009
   PubMed Web of Science ®Google Scholar
• Kelly DL, Sullivan KM, McEvoy JP, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015;35(4):374–381. doi: 10.1097/JCP.0000000000000345
   PubMed Web of Science ®Google Scholar
• Deakin B, Suckling J, Barnes TRE, et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry. 2018;5(11):885–894. doi: 10.1016/S2215-0366(18)30345-6
   PubMed Web of Science ®Google Scholar
• Shibre T, Alem A, Abdulahi A, et al. Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Schizophr Bull. 2010;36(4):846–851. doi: 10.1093/schbul/sbn191
   PubMed Web of Science ®Google Scholar
• Haskó G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol. 2013;4: doi: 10.3389/fimmu.2013.00085
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuro Psychopharmacol Biol Psychiatry. 2005;29(2):253–259. doi: 10.1016/j.pnpbp.2004.11.008
   PubMed Web of Science ®Google Scholar
• Allahham M, Lerman A, Atar D, et al. Why not dipyridamole: a review of current guidelines and re-evaluation of utility in the modern era. Cardiovasc Drugs Ther. 2022;36(3):525–532. doi: 10.1007/s10557-021-07224-9
   PubMed Web of Science ®Google Scholar
• Frampton MA, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane dementia and cognitive improvement group, editor. Cochrane Database Syst Rev. 2003. doi: 10.1002/14651858.CD002853
   PubMedGoogle Scholar
• Akhondzadeh Shasavand A, Shasavand S.J, et al. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J Clin Pharm Ther. 2000;25(2):131–137. doi: 10.1046/j.1365-2710.2000.00273.x
   PubMed Web of Science ®Google Scholar
• Wonodi I, Gopinath HV, Liu J, et al. Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmacology. 2011;218(2):341–345. doi: 10.1007/s00213-011-2315-3
   PubMed Web of Science ®Google Scholar
• Salimi S, Fotouhi A, Ghoreishi A, et al. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry. 2008;32(3):726–732. doi: 10.1016/j.pnpbp.2007.11.021
   PubMed Web of Science ®Google Scholar
• Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci, USA. 1998;95(13):7240–7244. doi: 10.1073/pnas.95.13.7240
   PubMed Web of Science ®Google Scholar
• Caldiroli A, Capuzzi E, Barkin JL, et al. Is there an association between inflammatory/anti-oxidant markers and the presence of psychotic symptoms or severity of illness in mood and psychotic disorders? A multi-centric study on a drug-free sample. Brain, Behavior, & Immun - Health. 2022;22:100453. doi:10.1016/j.bbih.2022.100453
   PubMedGoogle Scholar
• Lerner V, Miodownik C, Gibel A, et al. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin Neuropharmacol. 2008;31(1):25–33. doi: 10.1097/WNF.0b013e31806450da
   PubMed Web of Science ®Google Scholar
• Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry. 2003;60(2):133. doi: 10.1001/archpsyc.60.2.133
   PubMed Web of Science ®Google Scholar
• Ritsner MS, Gibel A, Shleifer T, et al. PregnenoLone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010;71(10):1351–1362. doi: 10.4088/JCP.09m05031yel
   PubMed Web of Science ®Google Scholar
• Marx CE, Keefe RSE, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacol. 2009;34(8):1885–1903. doi: 10.1038/npp.2009.26
   PubMed Web of Science ®Google Scholar
• Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial: adjunctive pregnenolone in schizophrenia. Psychiatry Clin Neurosci. 2014;68(6):432–440. doi: 10.1111/pcn.12150
   PubMed Web of Science ®Google Scholar
• Kardashev A, Ratner Y, Ritsner MS. Add-on pregnenolone with l-theanine to antipsychotic therapy relieves negative and anxiety symptoms of schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Clinical Schizophrenia & Related Psychoses. 2018;12(1):31–41. doi: 10.3371/CSRP.KARA.070415
   PubMedGoogle Scholar
• Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010;68(7):678–680. doi: 10.1016/j.biopsych.2010.04.039
   PubMed Web of Science ®Google Scholar
• Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr Res. 2011;132(1):50–53. doi: 10.1016/j.schres.2011.07.027
   PubMed Web of Science ®Google Scholar
• Modabbernia A, Rezaei F, Salehi B, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs. 2013;27(1):57–65. doi: 10.1007/s40263-012-0022-1
   PubMed Web of Science ®Google Scholar
• Gibson CM, Penn DL, Smedley KL, et al. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr Res. 2014 Jul;156(2–3):261–265.
   PubMed Web of Science ®Google Scholar
• Hwang WJ, Lee TY, Kim NS, et al. The role of estrogen receptors and their signaling across psychiatric disorders. IJMS. 2020;22(1):373. doi: 10.3390/ijms22010373
   Google Scholar
• Kianimehr G, Fatehi F, Hashempoor S, et al. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. DARU, J Pharm Sci. 2014;22(1):55. doi: 10.1186/2008-2231-22-55
   Google Scholar
• Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry. 2016;73(9):947. doi: 10.1001/jamapsychiatry.2016.1383
   PubMed Web of Science ®Google Scholar
• Khodaie-Ardakani M-R, Khosravi M, Zarinfard R, et al. A Placebo-controlled study of raloxifene added to risperidone in men with chronic schizophrenia. Acta Med Iran. 2015;53(6):337–345.
   PubMedGoogle Scholar
• Koch-Weser J. Diazoxide. N engl J med. 1976;294:1271–1274. doi: 10.1056/NEJM197606032942306
   PubMed Web of Science ®Google Scholar
• Patel JC, Witkovsky P, Coetzee WA, et al. Subsecond regulation of striatal dopamine release by pre-synaptic KATP channels: pre-synaptic KATP channels on dopaminergic axons. J Neurochem. 2011;118(5):721–736. doi: 10.1111/j.1471-4159.2011.07358.x
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Mojtahedzadeh V, Mirsepassi G-R, et al. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. J Clin Pharm Ther. 2002;27(6):453–459. doi: 10.1046/j.1365-2710.2002.00445.x
   PubMed Web of Science ®Google Scholar
• Jongkees BJ, Hommel B, Kühn S, et al. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands—A review. J Psychiatr Res. 2015;70:50–57. doi:10.1016/j.jpsychires.2015.08.014
   PubMed Web of Science ®Google Scholar
• Deutsch SI, Rosse RB, Schwartz BL, et al. L-Tyrosine pharmacotherapy of schizophrenia: preliminary data. Clin Neuropharmacol. 1994;17(1):53–62. doi: 10.1097/00002826-199402000-00006
   PubMed Web of Science ®Google Scholar
• Lopes Sakamoto F, Metzker Pereira Ribeiro R, Amador Bueno A, et al. Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia. Pharmacol Res. 2019;147:104395. doi:10.1016/j.phrs.2019.104395
   PubMed Web of Science ®Google Scholar
• Ritsner MS, Miodownik C, Ratner Y, et al. L-Theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011;72(1):34–42. doi: 10.4088/JCP.09m05324gre
   PubMed Web of Science ®Google Scholar
• Nasyrova RF, Ivashchenko DV, Ivanov MV, et al. Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. Front Physiol. 2015;6:6. doi:10.3389/fphys.2015.00139
   Web of Science ®Google Scholar
• Guimarães TM, Guimarães MRC, Oliveira ÍAF, et al. Mononitrate isosorbide as an adjunctive therapy in schizophrenia: a randomized controlled crossover trial. J Clin Psychopharmacol. 2021;41(3):260–266. doi: 10.1097/JCP.0000000000001388
   PubMed Web of Science ®Google Scholar
• Hallak JEC, Maia-de-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013;70(7):668. doi: 10.1001/jamapsychiatry.2013.1292
   PubMed Web of Science ®Google Scholar
• Capuzzi E, Caldiroli A, Ciscato V, et al. Experimental serotonergic agents for the treatment of schizophrenia. JEP. 2021;13:49–67. doi:10.2147/JEP.S259317
   Google Scholar
• Juza R, Vlcek P, Mezeiova E, et al. Recent advances with 5‐HT 3 modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev. 2020;40(5):1593–1678. doi: 10.1002/med.21666
   PubMed Web of Science ®Google Scholar
• Zhang Z-J, Kang W-H, Li Q, et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006;88(1–3):102–110. doi: 10.1016/j.schres.2006.07.010
   PubMed Web of Science ®Google Scholar
• Kim S-W, Kang H-J, Jhon M, et al. Statins and Inflammation: new therapeutic opportunities in psychiatry. Front Psychiatry. 2019;10:103. doi:10.3389/fpsyt.2019.00103
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Stock S, Borba CPC, et al. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res. 2014;159(2–3):395–403. doi: 10.1016/j.schres.2014.08.021
   PubMed Web of Science ®Google Scholar
• Ruiz-Castañeda P, Santiago Molina E, Aguirre Loaiza H, et al. Positive symptoms of schizophrenia and their relationship with cognitive and emotional executive functions. Cogn Research. 2022;7(1):78. doi: 10.1186/s41235-022-00428-z
   Google Scholar
• Farooq S, Agid O, Foussias G, et al. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull. 2013;39(6):1169–1172. doi: 10.1093/schbul/sbt137
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Ball MP, Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. AJP. 2005;162(1):124–129. doi: 10.1176/appi.ajp.162.1.124
   Google Scholar
• Samara MT, Nikolakopoulou A, Salanti G, et al. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? an analysis based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45(3):639–646. doi: 10.1093/schbul/sby095
   PubMed Web of Science ®Google Scholar
• Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017;74(7):675. doi: 10.1001/jamapsychiatry.2017.0624
   PubMed Web of Science ®Google Scholar
• Galderisi S, Kaiser S, Bitter I, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatr. 2021;64(1):e21. doi: 10.1192/j.eurpsy.2021.13
   PubMed Web of Science ®Google Scholar
• Ramadan E, Basselin M, Rao JS, et al. Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder. Int J Neuropsychopharm. 2012;15(7):931–943. doi: 10.1017/S1461145711001003
   PubMed Web of Science ®Google Scholar
• Egerton A, Grace AA, Stone J, et al. Glutamate in schizophrenia: neurodevelopmental perspectives and drug development. Schizophr Res. 2020;223:59–70. doi:10.1016/j.schres.2020.09.013
   PubMed Web of Science ®Google Scholar
• Zhai X, Zhou D, Han Y, et al. Noradrenergic modulation of stress resilience. Pharmacol Res. 2023;187:106598. doi:10.1016/j.phrs.2022.106598
   PubMed Web of Science ®Google Scholar
• Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol. 2002;25(2):107–110. doi: 10.1097/00002826-200203000-00009
   PubMed Web of Science ®Google Scholar
• Valença AGF, Smith BJ. Schizophrenia outside the brain. Adv Exp Med Biol. 2022;1400:53–63.
   PubMedGoogle Scholar
• Buoli M, Serati M, Caldiroli A, et al. Neurodevelopmental versus neurodegenerative model of schizophrenia and bipolar disorder: comparison with physiological brain development and aging. Psychiat Danub. 2017;29(1):24–27. doi: 10.24869/psyd.2017.24
   PubMed Web of Science ®Google Scholar
• Capuzzi E, Bartoli F, Crocamo C, et al. Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: a meta-analysis. Neuroscience & Biobehavioral Reviews. 2017;77:122–128. doi: 10.1016/j.neubiorev.2017.03.003
   PubMed Web of Science ®Google Scholar
• Pasquini S, Contri C, Borea PA, et al. Adenosine and inflammation: here, there and everywhere. IJMS. 2021;22(14):7685. doi: 10.3390/ijms22147685
   Google Scholar
• Siamwala JH, Dias PM, Majumder S, et al. L-Theanine promotes nitric oxide production in endothelial cells through eNOS phosphorylation. J Nutr Biochem. 2013;24(3):595–605. doi: 10.1016/j.jnutbio.2012.02.016
   PubMed Web of Science ®Google Scholar
• Gehlert DR, Robertson DW. ATP sensitive potassium channels: potential drug targets in neuropsychopharmacology. Prog Neuro Psychopharmacol Biol Psychiatry. 1994;18(7):1093–1102. doi: 10.1016/0278-5846(94)90113-9
   PubMed Web of Science ®Google Scholar
• Wołoszynowska-Fraser MU, Kouchmeshky A, McCaffery P. Vitamin A and retinoic acid in cognition and cognitive disease. Annu Rev Nutr. 2020;40(1):247–272. doi: 10.1146/annurev-nutr-122319-034227
   PubMedGoogle Scholar
• González-Rodríguez A, Seeman MV. Pharmacotherapy for schizophrenia in postmenopausal women. Expert Opin Pharmacother. 2018;19(8):809–821. doi: 10.1080/14656566.2018.1465563
   PubMed Web of Science ®Google Scholar
• Benarroch EE. Neurosteroids: endogenous modulators of neuronal excitability and plasticity. Neurology. 2007;68(12):945–947. doi: 10.1212/01.wnl.0000257836.09570.e1
   PubMed Web of Science ®Google Scholar
• Leucht S, Chaimani A, Krause M, et al. The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis. Lancet Psychiatry. 2022;9(11):884–893. doi: 10.1016/S2215-0366(22)00304-2
   PubMed Web of Science ®Google Scholar
• Altamura AC, Moliterno D, Paletta S, et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig. 2012;32(3):213–219. doi: 10.2165/11597330-000000000-00000
   PubMed Web of Science ®Google Scholar